title: Bupivacaine liposomal versus bupivacaine: comparative review.
abstract: Bupivacaine liposomal injection was recently approved by the US Food and Drug Administration (FDA) as a local anesthetic for use in management of postsurgical pain in adults. When compared to placebo, bupivacaine liposomal decreases postoperative pain and opioid use. This review examines the efficacy of bupivacaine liposomal when compared to conventional bupivacaine ± epinephrine using published and unpublished data provided to the FDA by the manufacturer.
authors: Clinical Coordinator, Upstate University Hospital at Community General , Syracuse, New York.
authors: John
authors: J
authors: Noviasky
authors: Assistant Professor of Pharmacy Practice, St. John Fisher College, Wegmans School of Pharmacy , Rochester, New York.
authors: Deirdre P
authors: DP
authors: Pierce
authors: Drug Information Pharmacist, St. Joseph's Hospital Health Center , Syracuse, New York.
authors: Karen
authors: K
authors: Whalen
authors: Professor of Medicine, University of Massachusetts Medical School , Worcester, Massachusetts.
authors: Roy
authors: R
authors: Guharoy
authors: Anesthesiologist, Upstate University Hospital at Community General , Syracuse, New York .
authors: Kenneth
authors: K
authors: Hildreth
keywords: bupivacaine; bupivacaine liposomal; formulary; pharmacoeconomics